



CellFace™ Cell-Antibody (Anti-NRP1) Conjugation

Cat. No.: CF-0922-ZP247

This product is for research use only and is not approved for use in humans or in clinical diagnosis.

Product Overview

Description

Employing live cells as therapeutics is a direction of future drug discovery. An easy and robust method to modify the surfaces of cells directly to incorporate novel functionalities is highly desirable. However, genetic methods for cell-surface engineering are laborious and limited by low efficiency for primary cell modification. Creative Biolabs has developed a single-step chemoenzymatic CellFace™ technology platform to transfer bio-macromolecules, such as an IgG antibody (MW~ 150 KD), to the glycocalyx on the surfaces of live cells. Requiring no genetic modification, our CellFace™ allows for any antibody to be conjugated to the stimulatory surface receptors of immune cells to yield the additive effect of superior tumor targeting to its already potent and off-the-shelf biologic drug payloads.

We applied CellFace™ to construct the CellFace™ cell-antibody conjugation (CAC). CellFace™ CAC can be prepared from multiple immune cells and stem cells, such as T cells, NK cells, macrophages, and mesenchymal stem cells. The modified CAC is expected to overcome the challenges that have prevented cell therapies from effectively targeting solid tumors.

Available Formats	CellFace™ T Cell-Antibody (Anti-NRP1) Conjugation CellFace™ NK Cell-Antibody (Anti-NRP1) Conjugation CellFace™ MA Cell-Antibody (Anti-NRP1) Conjugation CellFace™ MSC Cell-Antibody (Anti-NRP1) Conjugation CellFace™ HSC Cell-Antibody (Anti-NRP1) Conjugation
Engineered Molecules	Antibody
Cell Type	T Cell; NK Cell; Macrophage; HSC; MSC; TIL; CIK; γδ T Cell; Treg; Dendritic Cell; Fibroblast; Chondrocyte; iPSC; B Cell
Application Notes	The CAC can be customized with both cell lines and primary cells according to customer needs. Please contact us for specific cells you needs.

Target

Target	NRP1
--------	------

Official Name	NRP1
Full Name	Neuropilin 1
Synonyms	Vesencumab; 1205533-60-3; Anti-NRP1; RG7347; MNRP1685A; NRP1; neuropilin 1; neuropilin-1; CD304; NRP; VEGF165R; transmembrane receptor; vascular endothelial cell growth factor 165 receptor; NP1; BDCA4; DKFZp781F1414; DKFZp686A03134;

Quality Control

Research Use Only	For research use only, not for diagnostic or therapeutic use.
-------------------	---